Display options
Cite
Lowther DE, Goods BA, Lucca LE, et al. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight. 2016;1(5)doi: 10.1172/jci.insight.85935.
Lowther, D. E., Goods, B. A., Lucca, L. E., Lerner, B. A., Raddassi, K., van Dijk, D., Hernandez, A. L., Duan, X., Gunel, M., Coric, V., Krishnaswamy, S., Love, J. C., & Hafler, D. A. (2016). PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI insight, 1(5), . https://doi.org/10.1172/jci.insight.85935
Lowther, Daniel E, et al. "PD-1 marks dysfunctional regulatory T cells in malignant gliomas." JCI insight vol. 1,5 (2016). doi: https://doi.org/10.1172/jci.insight.85935
Lowther DE, Goods BA, Lucca LE, Lerner BA, Raddassi K, van Dijk D, Hernandez AL, Duan X, Gunel M, Coric V, Krishnaswamy S, Love JC, Hafler DA. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight. 2016 Apr 21;1(5). doi: 10.1172/jci.insight.85935. PMID: 27182555; PMCID: PMC4864991.
Copy Download .nbib Format: NLM
Share it on

JCI Insight. 2016 Apr 21;1(5). doi: 10.1172/jci.insight.85935.

PD-1 marks dysfunctional regulatory T cells in malignant gliomas.

JCI insight

Daniel E Lowther, Brittany A Goods, Liliana E Lucca, Benjamin A Lerner, Khadir Raddassi, David van Dijk, Amanda L Hernandez, Xiangguo Duan, Murat Gunel, Vlad Coric, Smita Krishnaswamy, J Christopher Love, David A Hafler

Affiliations

  1. Departments of Neurology and Immunobiology, Yale School of Medicine, New Haven, Connecticut, USA.
  2. Departments of Biological Engineering and Chemical Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
  3. Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.
  4. Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA; Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA.
  5. Bristol-Myers Squibb, Wallingford, Connecticut, USA.
  6. Departments of Biological Engineering and Chemical Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  7. Departments of Neurology and Immunobiology, Yale School of Medicine, New Haven, Connecticut, USA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

PMID: 27182555 PMCID: PMC4864991 DOI: 10.1172/jci.insight.85935

Abstract

Immunotherapies targeting the immune checkpoint receptor programmed cell death protein 1 (PD-1) have shown remarkable efficacy in treating cancer. CD4

References

  1. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 - PubMed
  2. J Immunol. 2002 May 1;168(9):4272-6 - PubMed
  3. Nature. 2012 Nov 22;491(7425):554-9 - PubMed
  4. BMC Bioinformatics. 2011 Aug 04;12:323 - PubMed
  5. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  6. Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7797-802 - PubMed
  7. Nat Med. 2004 Sep;10(9):942-9 - PubMed
  8. Genome Biol. 2010;11(10):R106 - PubMed
  9. J Exp Med. 2000 Jul 17;192(2):295-302 - PubMed
  10. Neuro Oncol. 2009 Aug;11(4):394-402 - PubMed
  11. Eur J Immunol. 2014 Sep;44(9):2703-11 - PubMed
  12. Nat Immunol. 2011 Jun;12(6):492-9 - PubMed
  13. Nature. 2013 Sep 12;501(7466):252-6 - PubMed
  14. Nat Immunol. 2005 Mar;6(3):280-6 - PubMed
  15. Sci Transl Med. 2015 May 13;7(287):287ra74 - PubMed
  16. Mol Cell Biol. 2005 Nov;25(21):9543-53 - PubMed
  17. Science. 2015 Apr 3;348(6230):56-61 - PubMed
  18. J Clin Invest. 2006 Sep;116(9):2423-33 - PubMed
  19. Eur J Immunol. 2008 Jun;38(6):1654-63 - PubMed
  20. PLoS One. 2015 May 06;10(5):e0126311 - PubMed
  21. Immunity. 2014 Feb 20;40(2):289-302 - PubMed
  22. Science. 1996 Mar 22;271(5256):1734-6 - PubMed
  23. Cell. 2015 Jul 2;162(1):184-97 - PubMed
  24. PLoS One. 2013;8(3):e58006 - PubMed
  25. Clin Cancer Res. 2013 Mar 1;19(5):1021-34 - PubMed
  26. Anal Chem. 2009 Aug 15;81(16):6813-22 - PubMed
  27. J Neuroimmunol. 2010 Aug 25;225(1-2):195-9 - PubMed
  28. Acta Neuropathol. 2007 Aug;114(2):97-109 - PubMed
  29. J Virol. 2006 Nov;80(22):11398-403 - PubMed
  30. J Clin Invest. 2015 Nov 2;125(11):4212-22 - PubMed
  31. Blood. 2007 Mar 1;109(5):2014-22 - PubMed
  32. Nat Biotechnol. 2013 Jun;31(6):545-52 - PubMed
  33. J Exp Med. 2009 Dec 21;206(13):3015-29 - PubMed
  34. Immunity. 2014 Apr 17;40(4):569-81 - PubMed
  35. Nat Rev Immunol. 2013 Apr;13(4):227-42 - PubMed
  36. Clin Cancer Res. 2008 Aug 15;14(16):5166-72 - PubMed
  37. Science. 2014 Nov 28;346(6213):1250689 - PubMed
  38. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 - PubMed
  39. Nature. 2006 Sep 21;443(7109):350-4 - PubMed
  40. J Clin Invest. 2009 Mar;119(3):551-64 - PubMed
  41. Immunity. 2007 Oct;27(4):670-84 - PubMed
  42. Genome Biol. 2009;10(3):R25 - PubMed
  43. Nucleic Acids Res. 2010 Jul;38(Web Server issue):W214-20 - PubMed
  44. Nucleic Acids Res. 2011 Oct;39(18):7946-60 - PubMed
  45. J Immunol. 2011 Apr 1;186(7):3918-26 - PubMed
  46. Cell. 2014 Aug 14;158(4):749-63 - PubMed
  47. Nat Immunol. 2015 Feb;16(2):188-96 - PubMed
  48. J Clin Invest. 2002 Jan;109(1):131-40 - PubMed
  49. Clin Cancer Res. 2003 Feb;9(2):606-12 - PubMed
  50. Nat Rev Immunol. 2015 Oct;15(10):596-7 - PubMed
  51. Immunity. 2012 Dec 14;37(6):1130-44 - PubMed
  52. Immunity. 2010 Jul 23;33(1):128-40 - PubMed
  53. Nat Med. 2011 Jun;17(6):673-5 - PubMed
  54. Immunity. 2015 Feb 17;42(2):239-51 - PubMed
  55. Nature. 2016 Jan 28;529(7587):532-6 - PubMed
  56. J Exp Med. 2004 Apr 5;199(7):971-9 - PubMed
  57. Cell Mol Immunol. 2010 Sep;7(5):389-95 - PubMed
  58. J Immunol. 2015 Jul 1;195(1):145-55 - PubMed
  59. N Engl J Med. 2012 Jun 28;366(26):2455-65 - PubMed
  60. J Immunol. 1999 Jun 15;162(12):7350-7 - PubMed
  61. Nat Med. 2014 Jan;20(1):69-74 - PubMed

Publication Types

Grant support